The Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study
An erratum to this article was published (J Clin Endocrinol Metab, 16 Oct 2025 ↗)
Main finding · AnemiaResult — go to the resultHazard ratio 0.6 95% CI 0.58–0.63Authors' conclusion
SGLT2 inhibitors demonstrated a lower prevalence of anemia and a lower risk of hospitalizations attributed to anemia when compared to treatment with DPP4 inhibitors in patients with diabetes.
Study context
- Population
- Patients with T2D, Clalit Health Services data repositories, January 1, 2016 – December 31, 2021matched cohort
- Participants
- 22,896 patients
- Exposure
- SGLT2 inhibitors vs DPP4 inhibitors
- SGLT2 inhibitorsn = 11,448
- Outcome
- Prevalence of anemia
Methodological detailspropensity-score matched, real-world data
- Propensity-score matched
- Real-world data
Main finding
Anemia
Hazard ratio
0.6
95% CI 0.58–0.63
SGLT2 inhibitorsvs DPP4 inhibitors
HR 0.6 (95% CI 0.58–0.63)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Hospitalizations attributed to anemia | 0.67 (0.58–0.77) | ||
| Necessity for anemia treatment | 0.84 (0.78–0.92) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Original publication
The Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study. J Clin Endocrinol Metab. Published 22 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →